DrugRisk Alert: Pradaxa Leads Study of Complication Reports to FDA

The DrugRisk Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options.

Dallas, TX (PRWEB) October 26, 2013

The prescription drug resource center DrugRisk.com is announcing new information on the site for patients taking the blood thinner Pradaxa. A recently published study identified the drug as the most often reported for serious side effects like internal bleeding*.

The news comes on the same day as a federal court disclosed the number of lawsuits alleging internal bleeding injuries has again grown**.

The DrugRisk center is a free resource for those taking popular prescription drugs. By providing the latest product recalls, safety alerts, research and litigation news, patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.

Pradaxa is a blood thinner approved by the FDA in 2010 as a stroke preventative for patients with atrial fibrillation. Experts disagree, however, about its risks for internal bleeding.

The FDA has advised Pradaxa is no more dangerous than traditional blood thinner warfarin***. Others, like the Institute for Safe Medication Practices, have warned that patients may be nearly 5 times as likely to die from Pradaxa bleeding than from warfarin bleeding****. A study this year from the Netherlands also suggested patients taking blood thinners like Pradaxa may be 55% more likely to suffer internal bleeding*****.

Now. DrugRisk has learned that the latest study from the Institute for Safe Medication Practices found Pradaxa ranked highest for number of complaints to the FDA last year, with 683 reports of bleeding*.

A growing number of patients have also filed a Pradaxa lawsuit alleging internal bleeding, leading to the consolidation of cases in a special federal multidistrict litigation court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

DrugRisk has added the latest court records from the Judicial Panel on Multidistrict Litigation, which show the number of cases filed has increased from 1,470 on September 11th to 1,643 on October 17, a rise of nearly 12% in less than a month**.

Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.

Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.

*Institute for Safe Medication Practices, 10/17/13; ismp.org/quarterwatch/pdfs/2012Q4.pdf
**Judicial Panel on Multidistrict Litigation, 10/17/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-October-17-2013.pdf
***FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
****Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
*****Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext


Contact